The company behind the world's first drug approved to treat low sexual desire in women is hoping to bring the "pink pill" to Australia. Sprout Pharmaceuticals - the company that on Wednesday won approval to sell its female libido drug "Addyi" in the US - wants to start working with international drug regulators to market the product globally. A spokeswoman could not say, however, when the company would apply to register the once-a-day pill with Australia's drug regulator, the Therapeutic Goods Administration. TGA registration is a necessary step for Australian doctors to prescribe the drug. From   October, Sprout Pharmaceuticals will sell the drug flibanserin under the name "Addyi" for women who haven't yet gone through menopause and suffer from low libido, according to a statement from the US drug regulatory agency. Flibanserin, a failed anti-depressant that will cost about $400 a month, led to a median of 0.5 to one extra "satisfying sexual event" a month for women in clinical studies.